How should I transition a patient on apixaban (Eliquis) to an unfractionated heparin drip, including appropriate drug‑free interval, dosing, and monitoring based on renal function and bleeding risk?

Transitioning from Apixaban to Unfractionated Heparin Drip

Stop apixaban and start unfractionated heparin (UFH) immediately without any drug-free interval in most clinical scenarios, as apixaban's short half-life (7-8 hours) and UFH's rapid onset allow safe overlap without bridging gaps. 1

Immediate Transition Protocol (Standard Approach)

For patients with normal to moderate renal function (CrCl >30 mL/min), discontinue apixaban and initiate UFH at the next scheduled apixaban dose time without waiting for drug clearance. 1

UFH Dosing Algorithm

• Loading dose: 80 units/kg IV bolus 1
• Maintenance infusion: 18 units/kg/hour, adjusted based on aPTT to maintain therapeutic range (1.5-2.5 times control) 1
• Target aPTT: Measure 6 hours after bolus and adjust infusion per institutional protocol 1

Rationale for Immediate Transition

• Apixaban has a half-life of 7-8 hours in normal renal function, meaning anticoagulant effect diminishes rapidly 2
• UFH achieves therapeutic anticoagulation within 1-2 hours of initiation 1
• The brief overlap period poses minimal bleeding risk compared to the thrombotic risk of a drug-free gap 1

Modified Protocol for Acute Kidney Injury (AKI)

In patients with acute kidney injury or severe renal impairment (CrCl 15-30 mL/min), measure apixaban-specific anti-Xa levels and delay UFH initiation until levels fall below 50-100 ng/mL. 3

AKI-Specific Considerations

• Apixaban clearance is prolonged in AKI, with only 27% renal elimination but significantly extended half-life 2, 3
• Check apixaban anti-Xa level at the time of the next scheduled dose 3
• Initiate UFH when apixaban anti-Xa <50 ng/mL for high bleeding-risk patients 3
• Initiate UFH when apixaban anti-Xa <100 ng/mL for standard-risk patients 3
• Expected clearance time: 36-56 hours after last apixaban dose in severe AKI 3

UFH Dosing in Renal Impairment

• Severe renal failure (CrCl <30 mL/min): Consider 50% dose reduction of standard UFH protocol and monitor aPTT more frequently (every 4 hours initially) 1, 4
• UFH does not require routine dose adjustment for renal dysfunction, but closer monitoring is essential 4
• Avoid enoxaparin in this population due to increased major bleeding risk (OR 1.84) compared to UFH 5

Renal Function Assessment

Calculate creatinine clearance using the Cockcroft-Gault equation with actual body weight, not eGFR, as this determines apixaban clearance and transition timing. 2

CrCl Range	Apixaban Half-Life	Transition Strategy
>50 mL/min	7-8 hours	Immediate transition [2]
30-50 mL/min	10-12 hours	Immediate transition with close aPTT monitoring [2]
15-30 mL/min	15-20 hours	Measure anti-Xa, delay UFH until <100 ng/mL [3]
<15 mL/min or dialysis	>24 hours	Measure anti-Xa, delay UFH until <50 ng/mL [3]

Drug Interaction Considerations

Screen for P-glycoprotein and strong CYP3A4 inhibitors (ketoconazole, ritonavir, itraconazole), which prolong apixaban clearance and may require extended monitoring before UFH initiation. 2

• If patient is taking combined P-gp and CYP3A4 inhibitors, extend the monitoring period by 24 hours 2, 6
• Strong CYP3A4 inducers (rifampin) accelerate clearance and allow earlier transition 2

Monitoring During Transition

Initial Phase (First 24 Hours)

• Baseline aPTT before UFH bolus 1
• aPTT at 6 hours after bolus, then every 6 hours until therapeutic 1
• Daily CBC to monitor for bleeding 1
• No INR monitoring needed as apixaban does not affect INR reliably 2

High-Risk Bleeding Scenarios

• Measure apixaban anti-Xa level if patient has received apixaban within 12 hours and has high bleeding risk (recent surgery, thrombocytopenia <50,000, active bleeding) 3
• Hold UFH initiation if apixaban anti-Xa >200 ng/mL in high bleeding-risk patients 3
• Consider prothrombin complex concentrate (PCC) 50 IU/kg if emergent reversal needed 6

Common Pitfalls to Avoid

• Do not use a "bridging gap" of 24-48 hours without anticoagulation, as this significantly increases stroke/thrombosis risk without reducing bleeding 6
• Do not rely on standard coagulation tests (PT/INR/aPTT) to assess residual apixaban effect; these are unreliable 6, 3
• Do not use enoxaparin instead of UFH in patients with CrCl <30 mL/min due to 84% increased major bleeding risk 5
• Do not calculate CrCl using eGFR; always use Cockcroft-Gault with actual body weight 2
• Do not assume normal clearance in elderly patients; a 78-year-old with "normal" creatinine may have CrCl <50 mL/min 3

Special Clinical Scenarios

Urgent/Emergent Surgery

• If surgery cannot be delayed: Measure apixaban anti-Xa level and proceed if <50 ng/mL 6, 3
• If anti-Xa >50 ng/mL: Consider PCC 50 IU/kg for reversal 6
• Resume UFH postoperatively at 24-48 hours once hemostasis confirmed 6

Atrial Fibrillation with High CHA₂DS₂-VASc Score

• Immediate transition is mandatory; any anticoagulation gap increases stroke risk exponentially 1
• Do not bridge with LMWH as this increases bleeding without benefit 6

Recent VTE (Within 3 Months)

• Immediate transition without gap is critical due to high recurrence risk 6
• Consider measuring anti-Xa only if severe renal impairment present 3